<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Non-alcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease (NAFLD) is the most common cause of <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> in Western World and frequently associated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and overweight and occurs often with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Interestingly, NAFLD is not only regarded as a hepatic component of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> but also as an independent risk factor and a marker for increase in <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Significantly, NAFLD is associated with an increased risk of <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality and predicts future <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> events independent of age, sex, <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> and features of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Although there was initial concern about drug toxicity with NAFLD, increasing evidence suggests that commonly used drugs such as <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="35664">statins</z:chebi> do not cause harm and the <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (TZDs) may even confer a therapeutic benefit in NAFLD </plain></SENT>
<SENT sid="4" pm="."><plain>Interestingly, medical and surgical treatments of <z:hpo ids='HP_0001513'>obesity</z:hpo> show potential benefit in treating NAFLD </plain></SENT>
<SENT sid="5" pm="."><plain>In this review, we have focused on the safety and therapeutic impact of TZDs, <z:chebi fb="0" ids="35664">statins</z:chebi>, <z:chebi fb="0" ids="6801">metformins</z:chebi> and <z:hpo ids='HP_0001513'>obesity</z:hpo> medications in NAFLD </plain></SENT>
<SENT sid="6" pm="."><plain>The potential benefit of bariatric surgery and the role of <z:hpo ids='HP_0001824'>weight loss</z:hpo> per se in treating NAFLD are also discussed </plain></SENT>
</text></document>